Myelodysplastic Syndrome Drug

Cornerstone Pharmaceuticals Has Received The US FDA Orphan Drug Designation
Oct 8, 2013
Cornerstone Pharmaceuticals has received the US Food and Drug Administration (FDA) orphan drug designation for its altered energy metabolism directed (AEMD) drug candidate 'CPI-613' for treatment of myelodysplastic syndrome (MDS). MDS is ...

Tags: Orphan Drug, Myelodysplastic Syndrome Drug